Vermillion, Inc. a molecular diagnostics company, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled “Biomarkers for breast cancer” to the Company. The patent claims are directed to biomarker combinations for the diagnosis and management of breast cancer and to the measurement of the biomarkers by mass spectrometry.

“The notice of allowance for this breast cancer biomarker patent is additional validation of our approach to intellectual property protection. We view the increasing breadth of our patent portfolio as a significant corporate asset,” said Gail S. Page, CEO and chairperson of the Board of Directors of Vermillion.

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients, along with its prestigious scientific collaborators, has diagnostic programs in oncology, haematology, cardiology and women's health.